About Intravacc
Intravacc, located at Utrecht Science Park Bilthoven in the Netherlands, is a leading global contract development and manufacturing organization (CDMO) of innovative vaccines against infectious diseases. As an established independent CDMO with an outstanding track record in vaccine development and vaccine technologies, Intravacc has transferred its technology related to polio vaccines, measles vaccines, DPT vaccines, Hib vaccines and influenza vaccines around the world. Around 40% of childhood disease vaccines are based on Intravacc’s proprietary technology. Intravacc offers a wide range of expertise to develop vaccine from concept to Phase I/II clinical studies for partners around the world, including universities, public health organizations (WHO, Bill & Melinda Gates Foundation), biotech and pharmaceutical companies. For more information, please visit Intravacc B.V.
About DZNE
The DZNE is a research institute funded by the German federal and state governments, comprising ten sites across Germany. It is dedicated to diseases of the brain and nervous system, such as Alzheimer’s, Parkinson’s, and ALS, which are associated with dementia, movement disorders and other serious health impairments. To date, there are no cures for these diseases, which represent an enormous burden for countless affected individuals, their families, and the healthcare system. The aim of DZNE is to develop novel strategies for prevention, diagnosis, care, as well as treatment, and to transfer them into practice. To this end, DZNE cooperates with universities, university hospitals, research centers and other institutions in Germany and abroad. The institute is a member of the Helmholtz Association and belongs to the German Centers for Health Research.
GA-VAX team members
GA-VAX team members at Intravacc
Dr. Corine Kruiswijk, Steering committee
Dr. Sabien van der Schoot, Steering committee
Dr. Robert van der Put, WP Lead (Business development)
Arnoud Spies, WP Lead (Production & QC)
Arno van der Ark, Project management
Patrick Burger, Regulatory affairs
Dr. Jolanda van den Hoven, Formulation development studies
Dr. Heleen Kraan, Preclinical studies
Dr. Thomas Michiels, Analytics & assay development
Joost Uittenbogaard, Analytics & assay development
Sacha Vervuurt, Analytics & assay development
GA-VAX team members at DZNE
Prof. Dieter Edbauer, Coordinator, Steering committee, WP Lead (Toxicology & safety, Project management)
Prof. Johannes Levin, Steering Committee, WP Lead (Clinical trial application)
Dr. Qihui Zhou, WP Lead (Efficacy)
Ruth Hossinger, Project management
Berkcan Isilgan, PhD student
Prof. Thomas Klopstock, Clinical trial planning
Julia Knogler, Technician
Virag Kocsis-Jutka, PhD student
Dr. Patrick Wunderlich, Technology transfer